[The role of immunooncology in the treatment of urothelial cancer].


Data published in November 2016 showed a significant survival benefit for the PD-1 antibody Pembrolizumab in the second-line treatment of metastatic urothelial cancer in comparison to standard chemotherapy. Other PD-1/PD-L1 antibodies are being tested in advanced clinical trials. This class of substances will become standard of care from the time of their… (More)
DOI: 10.1055/s-0043-107041


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.